Levosimendan 是一种钙增敏剂，通过以钙依赖性方式与心肌肌钙蛋白 C 结合，增加肌细胞对钙的敏感性来发挥其作用，可治疗急性失代偿性充血性心力衰竭。

Levosimendan is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner.

Levosimendan（0.03-0.1 μM）是较好的Ca2+增敏剂,而浓度为0.1到0.3 μM时,作为磷酸二酯酶抑制剂,对正性肌力作用有利.

Levosimendan可使衰竭的人心肌细胞收缩和松弛,0.8 μM Levosimendan下的抽搐张力平均最大增加47%。Levosimendan可引起代偿性心脏衰竭患者体内血液动力学函数快速剂量依赖性增长。Levosimendan使大鼠肠系膜动脉肌细胞的静息电位明显超极化（EC50：2.9 μM）,10 μM的作用最大(19.5 mV),这可能是通过激活格列本脲敏感性K+通道产生的。Levosimendan（3 μM）可使Ca50从2.73 μM减少至1.19 μM。

141505-33-1

C14H12N6O

280.291

OR1855;左西孟旦;OR1259

Ethanol:<1 mgml
DMSO:52 mg/mL (185.5 mM)
H2O:<1 mgml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years